Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine

NCT02475278 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Norovirus
Healthy Participants

Interventions

BIOLOGICAL: NoV GI.1/GII.4 Bivalent VLP Vaccine

Sponsor

Takeda